Pancreatic Cancer Drug, USPSTF, Tylenol-Autism

Pancreatic Cancer Drug, USPSTF, Tylenol-Autism

September 11, 2026 · 1h 42m · Episode 41

About this episode

The episode discusses a new pancreatic cancer drug, evidence-based guidelines, and the role of AI in medicine, among other topics.

We're trying to become better listeners, SO PREPARE FOR SOME SHOUTING 🤭 Originally streamed ⁠LIVE on YouTube⁠! (#41) We cover the new pancreatic cancer drug daraxonrasib and its rash side effect, survival benefit, and cost; what makes pancreatic cancer especially deadly; Vinay’s clinical background across hematology and oncology; how mechanistically cancer actually kills; the challenge of finding good podcast guests and why authenticity matters more than plugging a product; vaccine mandates and the difference between individual versus population-level benefit; the USPSTF’s recent upheaval and the challenge of evidence-based guidelines on contested topics like depression screening, mammograms, and prostate cancer screening; observational versus randomized evidence, with examples spanning flu vaccines, shingles vaccines and dementia, and Tylenol in pregnancy and autism; the OpenAI Navier-Stokes controversy and AI’s role in mathematics; AI in medicine and a JAMA perspective piece on AI replacing physicians; statins, coronary calcium scores, and personal decision-making around cardiovascular risk; weight stigma in medical training and the complexity of obesity; alternative medicine…

People in this episode

Hosts: Dr. Vinay Prasad, Zubin Damania

Topics covered

Keywords

Mentioned in this episode

Organizations: USPSTF, OpenAI, JAMA

Products: daraxonrasib

More episodes of The VPZD Show

Explore listener stats, chart rankings, contacts and more on the The VPZD Show podcast page.